Proprietary Cell-Line Development for High-Titer AAV Manufacturing: Proprietary cell lines offer opportunities for achieving high AAV titers.
| Publicado en: | BioPharm International Vol. 37; no. 3; pp. 10 - 15 |
|---|---|
| Autor principal: | |
| Formato: | pictorial Journal Article |
| Publicado: |
MJH Life Sciences
Mar2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=176164782&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 176164782 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1542166X 5NE jtl: BioPharm International issn: 1542166X maglogo: N pubinfo: dt: Mar2024 vid: 37 iid: 3 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 176164782 176164782 176164782 176164782 ppf: 10 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Proprietary Cell-Line Development for High-Titer AAV Manufacturing: Proprietary cell lines offer opportunities for achieving high AAV titers. aug: au: CHALLENER, CYNTHIA A. sug: subj: Cell Line Cell Physiology Viruses Biological Products Costs and Cost Analysis Genetic Engineering Gene Therapy Cell Viability pubtype: Trade Publication doctype: pictorial Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|